Bluejay Diagnostics, Inc.

Equities

BJDX

US0956333019

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-14 EDT			5-day change	1st Jan Change
0.51 ^USD	+11.62%		+17.78%	-58.20%

05-31	Bluejay Diagnostics, Inc. announced a financing transaction	CI
05-15	Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Bluejay Diagnostics, Inc. Completes Planned Clinical Studies for Symphony IL-6 Test

July 06, 2022 at 07:30 am

Bluejay Diagnostics, Inc. announced completion of its previously planned clinical studies for the Symphony IL-6 Test. Results of these studies will be published at the 2022 AACC Annual Scientific Meeting being held July 26th to 28th in Chicago.

Latest news about Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. announced a financing transaction	05-30	CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Bluejay Diagnostics, Inc. Appoints Neil Dey as Principal Financial and Accounting Officer	04-02	CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Top Premarket Decliners	12-28	MT
Top Midday Decliners	12-27	MT
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients	12-27	CI
Bluejay Diagnostics Starts Clinical Study of Symphony IL-6 Test in Sepsis Patients; Shares Fall	12-27	MT
Bluejay Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Bluejay Diagnostics, Inc. Announces CFO Changes	23-10-02	CI
Bluejay Diagnostics, Inc. announced that it has received $1.59084 million in funding	23-08-27	CI
Sector Update: Health Care Stocks Climbing Late Afternoon	23-08-25	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-08-25	MT
Bluejay Diagnostics to Raise $1.6 Million in Registered Direct Offering	23-08-25	MT
Bluejay Diagnostics, Inc. announced that it expects to receive $1.59084 million in funding	23-08-23	CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
North American Morning Briefing : Stocks Seen -2-	23-08-04	DJ
Dawson James Downgrades Bluejay Diagnostics to Neutral From Buy	23-08-03	MT
Bluejay Diagnostics Files $25 Million Mixed Shelf	23-06-06	MT
Bluejay Diagnostics, Inc. Updates Symphony IL-6 Regulatory Strategy	23-05-19	CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Sector Update: Health Care Stocks Lifted with Broader Markets	23-03-21	MT
Top Midday Decliners	23-03-21	MT
Sector Update: Health Care Stocks Still Struggling for Firm Direction Tuesday Afternoon	23-03-21	MT
Top Premarket Decliners	23-03-21	MT

Chart Bluejay Diagnostics, Inc.

Duration

Period

More charts

Company Profile

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.

Sector

Biotechnology & Medical Research

Calendar

2024-11-06 - Q3 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
BLUEJAY DIAGNOSTICS, INC.	-58.20%	1.48M
EXACT SCIENCES CORPORATION	-43.39%	7.73B
GUARDANT HEALTH, INC.	+11.68%	3.7B
IOVANCE BIOTHERAPEUTICS, INC.	+0.37%	2.28B
BGI GENOMICS CO., LTD.	-21.21%	1.99B
VERACYTE, INC.	-23.77%	1.6B
CAREDX, INC	+18.25%	739M
SEEGENE, INC.	-10.04%	687M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-36.12%	461M
CURIOX BIOSYSTEMS CO., LTD	-4.47%	279M

Bio Diagnostics & Testing